201. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial.
- Author
-
Tibau A, Martínez MT, Ramos M, De La Cruz-Merino L, Santaballa A, O'Connor M, Martínez-Jañez N, Moreno F, Fernández I, Virizuela JA, Alarcón J, de La Haba-Rodríguez J, Sánchez-Rovira P, Albacar CR, Bueno Muiño C, Kelly C, Casas M, Bezares S, Rosell L, and Albanell J
- Abstract
Background: In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression-free survival (PFS) compared with placebo/fulvestrant in postmenopausal women with HR+/HER2- advanced breast cancer (ABC)., Objective: We assessed health-related quality of life (QoL) using patient-reported outcomes (PROs)., Design and Methods: In this phase II double-blinded study, PROs were assessed at baseline after every three cycles and at the end of the treatment using the European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-BR23. Time to deterioration (TTD) in global health status (GHS)/QoL was defined as a decrease of ⩾10 points. Changes from baseline (CFB) and TTD were analysed using linear mixed-effect and Cox regression models, respectively., Results: Of the 189 randomised (1:1) patients, 178 (94%) completed ⩾1 post-baseline assessment; 50% received ⩾22 cycles of study treatment, with a questionnaire compliance >90%. Mean baseline scores were comparable between arms. GHS/QoL scores were maintained throughout the palbociclib/fulvestrant treatment. CFB showed significant differences for GHS/QoL, appetite loss, constipation and systemic therapy side effect scores favouring placebo/fulvestrant. TTD in GHS/QoL was delayed in placebo/fulvestrant versus palbociclib/fulvestrant [30.3 versus 11.1 months; adjusted hazard ratio (aHR): 1.57, 95% CI: 1.03-2.39, p = 0.036]; this difference was not significant in patients with progressive disease (aHR: 1.2, 95% CI: 0.6-2.2, p = 0.658). No statistically significant differences in TTD were found for the other QLQ-C30 and QLQ-BR23 scales., Conclusions: Although TTD in GHS/QoL was prolonged with placebo/fulvestrant, no differences were observed on other functional or symptom scales. This finding and the improvement in PFS support the combination of palbociclib/fulvestrant as a beneficial therapeutic option for HR+/HER2- ABC., Trial Registration Number: Sponsor Study Code: GEICAM/2014-12EudraCT Number: 2015-002437-21ClinTrials.gov reference: NCT02690480., Competing Interests: Dr. Tibau has received speaker fees from Novartis and Eisai. Dr. Ramos has received speaker’s bureau from Novartis, Pfizer and Roche Farma. Dr. de La Cruz-Merino has received advisory board fees from MSD-Merk, Roche Farma, Bristol-Myers-Squibb, Pierre-Fabré, Amgen and Novartis; research funding from MSD-Merck, Roche Farma, Celgene; speaking fees from MSD-Merck, Roche Farma, Bristol-Myers-Squibb and Amgen; grant support from Bristol-Myers-Squibb and Roche Farma. Dr. Santaballa has received consulting or advisory role fees from GSK, Clovis, MSD, AstraZeneca, Roche and Pfizer; speakers’ honoraria from GSK, Clovis, Roche, MSD, AstraZeneca and Pfizer; and grant support by Pfizer, GSK and MSD. Dr. Martínez-Jañez has received advisory board fees from Roche Farma, Astra Zeneca, Pfizer, Novartis, Lilly, Daiichi Sankyo, Agendia and Eisai. Dr. Moreno has received advisory board fees from Roche/Genentech, Novartis, Pfizer, AstraZeneca, MSD-Merck and Daiichi Sankyo/AstraZeneca; speaker’s bureau fees from Pfizer; travel accommodations expenses from Roche/Genentech, Pfizer, Novartis, Daiichi Sankyo/Astra Zeneca. Dr. Fernández has received consultant or advisory fees from MSD-Astra Zeneca; speaker’s bureau fees from Pfizer, AstraZeneca, Roche, MSD, Clovis and GSK. Dr. Alarcón: has received honoraria from GSC, Clovis, Roche and AstraZeneca; consulting or advisory board honoraria from GSK and Clovis; speaker and expert testimony fees from GSK, Clovis and Roche; and travel and accommodation support from GSK. Dr. de La Haba-Rodríguez has received speaker’s honoraria from AstraZeneca, Pfizer, Novartis and Lilly. Dr. Sánchez-Rovira has received honoraria from Novartis, Lilly, Pfizer, Roche and Seagen. Dr. Bueno Muiño has received speaker fees from Novartis, Lilly, AstraZeneca, BMS, Pfizer and GSK. Dr. Albanell has received consulting or advisory role fees from Roche, Pfizer, Amgen, MSD, Lilly and Daiichi-Sankyo; research funding or grant support trials by Roche, Pfizer, Amgen, MSD, Lilly, Daiichi-Sankyo; and travel and accommodation support from Roche, Pfizer, Amgen, MSD, Lilly and Daiichi-Sankyo. All remaining authors have declared no conflicts of interest. GEICAM has received research funding from Roche/Genentech, Bristol-Myers Squibb, Novartis, Pfizer, Celgene, AstraZeneca, Merck Sharp & Dohme, Pierre Fabre and Takeda. A complete list of the FLIPPER trial collaborators is provided in the Supplemental Appendix., (© The Author(s), 2023.)
- Published
- 2023
- Full Text
- View/download PDF